Zydus Cadilla seeks DCGI’s approval to undertake clinical trials for monoclonal antibodies cocktail

 

 

@DDNewslive

Pharmaceutical Company Zydus Cadilla has sought Drug Controller General of India’s(DCGI) approval to undertake clinical trials for monoclonal antibodies cocktail that can neutralise Covid infection. India’s leading Indian Pharmaceutical company Zydus Cadilla Healthcare has announced biological therapy ZRC-3308 for the treatment of mild COVID-19 symptoms. ZRC-3308 is a cocktail of two anti-SARS-CoV-2 monoclonal antibodies.
 
Managing Director of Cadila Healthcare Limited, Dr. Sharvil Patel has said that there is a critical need to explore safe and more efficacious treatment to combat Covid at this juncture. He said, it is important to look at different stages of the disease progression and options that can reduce a patient's suffering and discomfort. Mr. Patel believed that ZRC-3308 has the potential to address these concerns and provide safe treatment. 

 

Social media is bold. 

Social media is young.

Social media raises questions.

 Social media is not satisfied with an answer.

Social media looks at the big picture.

 Social media is interested in every detail.

social media is curious.

 Social media is free.

Social media is irreplaceable.

But never irrelevant.

Social media is you.

(With input from news agency language)

 If you like this story, share it with a friend!  

We are a non-profit organization. Help us financially to keep our journalism free from government and corporate pressure.